The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Institutional ownership in the company is 76.40% while the short ratio is 1.88.
Merck & Co., Inc.'s Quick Ratio shows the value of 1.5.
A number of other institutional investors have also modified their holdings of MRK. 4,477 shares or 100.00% less from 162.57 million shares in 2016Q3 were reported. (NYSE:CBB). Alphamark Advsr Ltd Com owns 1,080 shares for 0.01% of their portfolio. Over the last three months, insiders have sold 63,850 shares of company stock valued at $4,063,048. Finally, Tortoise Investment Management LLC raised its position in Merck & Co.by 50.6% in the fourth quarter. Farmers & Merchants Investments Inc. now owns 95,626 shares of the company's stock worth $5,968,000 after buying an additional 10,466 shares during the period.
The ability for Merck & Co., Inc., to deal with debt, means it current ratio is 1.8, and quick ratio is 1.5.
Earnings per share (EPS) breaks down the profitability of the company on a single share basis, and for Merck & Co., Inc. the EPS stands at 0.88 for the previous quarter, while the analysts predicted the EPS of the stock to be 0.83, suggesting the stock exceeded the analysts' expectations. Barclays Capital upgraded the stock to "Overweight" rating in Tuesday, December 1 report.
The 52 week high is -4.06%, with 23.61% being its 52 week low. (NYSE:MRK) was up +1.48% during the last trading session, with a day high of 63.67. In this case, shares are 48.46% higher from $9.7, the worst price in 52 weeks suffered on Jul. 06, 2016, and are keeping their losses at 4.93% for the past six months. The stock has a market capitalization of $175.63 billion, a P/E ratio of 45.37 and a beta of 0.79. The Return on Equity ratio of Merck & Co., Inc. (NYSE:MRK)'s earnings per share has been growing at a -7 percent rate over the past 5 year when average revenue increase was noted as -3.7 percent. (NYSEMKT:CET) to report $0.00 EPS on May, 10.
European Union hangs in the balance as France votes
Meanwhile, a win for Le Pen was expected to hurt the euro by as much as six percent, according to Deutsche Bank estimates. Macron is running on a pro-EU platform, promising to reform the union and bring back economic prosperity to France.
12 analysts on average are expecting the company to report revenue of $9.68 Billion for the current quarter. MRK generated revenue of $9.32 Billion in the same quarter, one year ago. Equities research analysts forecast that Merck & Co., Inc. will post $3.82 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, April 7th. Rowland And Comm Investment Counsel Adv invested in 0% or 53,616 shares.
The dividend yield for the company is hovering around 2.95% while the pay out ratio is now at 130.00%. The ex-dividend date was Monday, March 13th.
04/10/2017 - Merck & Company, Inc. had its "market perform" rating reiterated by analysts at Cowen. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of worldwide trademark & copyright legislation. (NYSE:MRK) is trading at, 63.63 (1.48% today), Merck & Co., Inc. has a dividend yield of 2.95%, and this is covered by a payout ratio of 130.00%. Inc. has $72 highest and $50 lowest target. (NYSE:MRK)'s stock had its "outperform" rating reiterated by investment analysts at BMO Capital Markets in a report released on Sunday, April 23rd. It helps investors in determining whether buying, selling or holding on to a stock would be beneficial for them. Finally, Jefferies Group LLC reissued an "underperform" rating and issued a $52.00 target price (up previously from $50.00) on shares of Merck & Co.in a research note on Saturday, March 11th. Recently, investment analysts covering the stock have updated the mean rating to 2.
Merck & Co, Inc is a global healthcare company. Also, Director Patricia F. Russo sold 5,000 shares of the business's stock in a transaction dated Wednesday, February 8th. Average volume for Merck & Co., Inc., is 8881.77, and so far today it has a volume of 11361900. Following the transaction, the director now directly owns 5,100 shares in the company, valued at approximately $329,001. The stock was sold at an average price of $63.48, for a total value of $3,418,398.00. The disclosure for this sale can be found here.
On the last trading day, Merck & Co., Inc. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four divisions: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Comments